This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Neovasc Past Earnings Performance

Past criteria checks 0/6

Key information

24.01%

Earnings growth rate

101.80%

EPS growth rate

Medical Equipment Industry Growth-19.22%
Revenue growth rate-4.31%
Return on equity-260.14%
Net Margin-1,082.90%
Last Earnings Update31 Dec 2022

Recent past performance updates

Recent updates

Is Neovasc (TSE:NVCN) Using Too Much Debt?

Jan 06
Is Neovasc (TSE:NVCN) Using Too Much Debt?

Is Neovasc (TSE:NVCN) Using Debt Sensibly?

Jun 11
Is Neovasc (TSE:NVCN) Using Debt Sensibly?

What You Need To Know About Neovasc Inc.'s (TSE:NVCN) Investor Composition

Feb 14
What You Need To Know About Neovasc Inc.'s (TSE:NVCN) Investor Composition

Revenue & Expenses Breakdown

How Neovasc makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

TSX:NVCN Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 224-411918
30 Sep 223-341315
30 Jun 223-331415
31 Mar 223-331414
31 Dec 213-251615
30 Sep 212-231718
30 Jun 212-261920
31 Mar 212-271920
31 Dec 202-291620
30 Sep 202-371621
30 Jun 202-331321
31 Mar 202-311220
31 Dec 192-351220
30 Sep 192-111418
30 Jun 192-201817
31 Mar 192-611716
31 Dec 182-1081616
30 Sep 182-1251915
30 Jun 183-1151416
31 Mar 184-711416
31 Dec 175-221416
30 Sep 17719719
30 Jun 179-5719
31 Mar 179-83720
31 Dec 1610-86719
30 Sep 169-131719
30 Jun 168-110719

Quality Earnings: NVCN is currently unprofitable.

Growing Profit Margin: NVCN is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: NVCN is unprofitable, but has reduced losses over the past 5 years at a rate of 24% per year.

Accelerating Growth: Unable to compare NVCN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NVCN is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-1.9%).


Return on Equity

High ROE: NVCN has a negative Return on Equity (-260.14%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/04/13 00:01
End of Day Share Price 2023/04/10 00:00
Earnings2022/12/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Neovasc Inc. is covered by 10 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David MartinBloom Burton & Co.
Jason MillsCanaccord Genuity
John GillingsCitizens JMP Securities, LLC